Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Recruiting · NCT05310643 · Registry updated 2025-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-07-01 | NCT05310643 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GERCOR - Multidisciplinary Oncology Cooperative Group | 25 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Antoine Lacassagne | Nice | France | 60 |
| Centre Léon Bérard | Lyon | France | 71 |
| CHRU Lille | Lille | France | 32 |
| Chu Dupuytren | Limoges | France | 15 |
| CHU Jean Minjoz | Besançon | France | 13 |
| CHU Poitiers | Poitiers | France | 70 |
| Hôpital Saint Antoine | Paris | France | 21 |
| ICM Val d'Aurelle | Montpellier | France | 6 |
| Institute Bergonie | Bordeaux | France | 1 |